Standard versus Reduced-Dose Valganciclovir CMV Prophylaxis in High-Risk Liver Transplant Recipients

被引：0
|
作者：
Dann, J. [1 ]
Geyston, J. [1 ]
Majmundar, D. [1 ]
Haywood, S. [1 ]
Shoemaker, C. [1 ]
Pelletier, S. [1 ]
Wentworth, B. [1 ]
机构：
[1] UVA Univ Virginia Hlth, Charlottesville, VA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
120
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [21] Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
    Kletzmayr, J
    Kotzmann, H
    PopowKraupp, T
    Kovarik, J
    Klauser, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (02): : 325 - 330
  • [22] Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients.
    Helantera, I.
    Ortiz, F.
    Loginov, R.
    Mannonen, L.
    Lempinen, M.
    Lautenschlager, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 533 - 533
  • [23] Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis
    Kalil, Andre C.
    Mindru, Cezarina
    Botha, Jean F.
    Grant, Wendy J.
    Mercer, David F.
    Olivera, Marco A.
    McCartan, Megan A.
    McCashland, Timothy M.
    Langnas, Alan N.
    Florescu, Diana F.
    LIVER TRANSPLANTATION, 2012, 18 (12) : 1440 - 1447
  • [24] COMPARISON OF VALGANCICLOVIR VERSUS GANCICLOVIR FOR CMV PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS- A SINGLE CENTER STUDY
    Bedel, Ashley N.
    Hemmelgarn, Trina S.
    Kohli, Rohit
    HEPATOLOGY, 2011, 54 : 706A - 706A
  • [25] Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection
    Boutolleau, David
    Deback, Claire
    Bressollette-Bodin, Celine
    Varnous, Shaida
    Dhedin, Nathalie
    Barrou, Benoit
    Vernant, Jean-Paul
    Gandjbakhch, Iradj
    Imbert-Marcille, Berthe-Marie
    Agut, Henri
    ANTIVIRAL RESEARCH, 2009, 81 (02) : 174 - 179
  • [26] Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients
    Bodro, Marta
    Sabe, Nuria
    Llado, Laura
    Baliellas, Carme
    Niubo, Jordi
    Castellote, Jose
    Fabregat, Joan
    Rafecas, Antoni
    Carratala, Jordi
    LIVER TRANSPLANTATION, 2012, 18 (09) : 1093 - 1099
  • [27] Valganciclovir approved for the prevention of CMV in high-risk kidney, kidney-pancreas transplant recipients
    不详
    DIALYSIS & TRANSPLANTATION, 2003, 32 (11) : 646 - 646
  • [28] Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients
    Park, Jeong M.
    Lake, Kathleen D.
    Fontana, Robert J.
    LIVER TRANSPLANTATION, 2006, 12 (06) : 1022 - 1023
  • [29] Standard-versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients.
    Wilson, N.
    Sulejmani, N.
    Jantz, A.
    Patel, A.
    Summers, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 532 - 532
  • [30] Outcomes of antifungal prophylaxis in high-risk liver transplant recipients
    Hadley, S.
    Huckabee, C.
    Pappas, P. G.
    Daly, J.
    Rabkin, J.
    Kauffman, C. A.
    Merion, R. M.
    Karchmer, A. W.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (01) : 40 - 48
12345